Get the Stockscreener App
10.16
0.89%
0.09
Entrada Therapeutics Inc stock is traded at $10.16, with a volume of 78,403.
It is up +0.89% in the last 24 hours and up +53.47% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$10.07
Open:
$9.94
24h Volume:
78,403
Relative Volume:
0.28
Market Cap:
$388.31M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
3.4324
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
+0.79%
1M Performance:
+53.47%
6M Performance:
+28.12%
1Y Performance:
-49.10%
1-Day Range:
$9.52
$10.38
1-Week Range:
$9.40
$10.38
52-Week Range:
$4.93
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.16 | 384.87M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Insider Sell: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus
Entrada Therapeutics CFO Sells Shares Under Trading Plan - TradingView
CFO Wentworth Sells 8,910 ($88.9K) Of Entrada Therapeutics Inc [TRDA] - TradingView
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
CFO Wentworth Files To Sell 8,910 Of Entrada Therapeutics Inc [TRDA] - TradingView
Will Entrada Therapeutics Inc. stock deliver shareholder valueWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Entrada Therapeutics (TRDA) Price Target Decreased by 10.81% to 16.83 - MSN
Why Entrada Therapeutics Inc. stock is favored by pension fundsTrade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
(TRDA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Questex’s Fierce Life Sciences Announces 2025 Innovation Awards Winners - GlobeNewswire Inc.
How risky is Entrada Therapeutics Inc. stock now2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Can Entrada Therapeutics Inc. stock resist market sell offs2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Major Stock Sell-Offs at Entrada Therapeutics Inc! - TipRanks
Applying big data sentiment scoring on Entrada Therapeutics Inc.2025 Top Decliners & Consistent Return Investment Signals - newser.com
Owner 5AM Ventures V LP Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Chmn Parmar Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Is Entrada Therapeutics Inc a good long term investmentEarnings Growth Projections & Real-Life Case Studies You Can Follow - earlytimes.in
Real time pattern detection on Entrada Therapeutics Inc. stockWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha
Published on: 2025-11-16 13:38:00 - newser.com
Multi factor analysis applied to Entrada Therapeutics Inc.July 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Is Entrada Therapeutics Inc. forming a bottoming basePortfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
How Entrada Therapeutics Inc. stock benefits from strong dollarJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Published on: 2025-11-19 18:26:53 - newser.com
Owner 5AM Ventures V LP Files To Sell 200,000 Of Entrada Therapeutics Inc [TRDA] - TradingView
Entrada Therapeutics Eyes 2026 Trial Data With Cash Runway Into 2027 - RTTNews
Published on: 2025-11-13 23:16:53 - newser.com
Will Entrada Therapeutics Inc. stock gain from strong economyForecast Cut & AI Forecast Swing Trade Picks - newser.com
Understanding Entrada Therapeutics Inc.’s price movement2025 EndofYear Setup & Community Consensus Trade Alerts - newser.com
Does Entrada Therapeutics Inc. stock trade at a discount to peersJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):